BiotechTube
Aer Therapeutics

Aer Therapeutics

San Diego, United States· Est.
aertherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $76M

Overview

Aer Therapeutics is a private, clinical-stage biotech targeting a significant unmet need in chronic obstructive pulmonary disease (COPD) and asthma: mucus plugs. Its lead asset, AER-01, is an inhaled small molecule therapy designed to cleave the chemical bonds that thicken mucus, aiming to clear airways, restore lung function, and reduce inflammation. The company has initiated a Phase 2a proof-of-concept study in COPD and is positioning itself as a pioneer in the mucolytic space for these prevalent respiratory conditions.

RespiratoryCOPDAsthma

Technology Platform

Inhaled small molecule platform designed to cleave specific chemical bonds that cross-link mucin strands, liquifying pathological mucus plugs in the airways.

Funding History

2
Total raised:$76M
Venture$36M
Series A$40M

Opportunities

AER-01 targets a large, underserved patient population of over 6.5 million in the U.S.
alone with mucus-plugged COPD or asthma, representing a potential multi-billion dollar market.
Success could establish a new therapeutic class (mucolytics) for chronic lung disease and enable more effective use of existing standard-of-care inhalers.

Risk Factors

The novel mechanism of AER-01 is unproven in late-stage human trials, posing significant clinical efficacy and safety risks.
As a private, pre-revenue company, Aer is dependent on venture funding and vulnerable to capital market conditions, with regulatory and future commercialization challenges ahead.

Competitive Landscape

The direct competitive landscape for a targeted mucolytic in COPD/asthma is currently sparse, with no approved therapies specifically for mucus plugs. However, AER-01 would compete for market share within the broad, crowded respiratory drug market dominated by bronchodilators, steroids, and biologics. Its success depends on demonstrating additive clinical benefit to these existing standards.

More companies in Small Molecule Drugs →More companies in United States →